close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Myriad Genetics, Inc.

< Previous 1 2 3 4 5 Next >
Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers ILMN MYGN
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today